Abstract
Abstract“Atypical” antipsychotic drugs are widely used in patients with neurobehavioral disturbances related to dementia. Recent reports have highlighted the risks of these agents, including increased mortality, and the US Food and Drug Administration (FDA) has issued black-box warnings concerning their use. Studies of efficacy have shown only limited evidence that these drugs are more effective than placebo in controlling abnormal behaviors or improving the lives of patients with dementia and their caregivers. Recent evidence suggests that the older, “typical” antipsychotic drugs have at least as much risk as the atypical agents, and FDA warnings have been extended to these agents. In managing the behavioral disturbances of demented patients, clinicians must weigh the benefits and risks of these agents, use them only for severely disruptive behaviors, discontinue medications when ineffective, and inform families of the benefits and risks of treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Tariot PN, Podgorski CA, Blazina L, et al.: Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993, 39:440–449.
Holmes C, Wilkinson D, Dean C, et al.: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer’s disease. Neurology 2004, 63:214–219.
Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308–2314.
Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001, 57:613–620.
Tariot PN, Cummings JL, Katz IR, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001, 49:1590–1599.
Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002, 359:1283–1290.
McKeith I, Del Ser T, Spano P, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356:2031–2036.
Courtney C, Farrell D, Gray R, et al.: Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet 2004, 363:2105–2015.
Cummings JL, Schneider E, Tariot PN, et al.: Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006, 67:57–63.
De Deyn PP, Katz IR, Brodaty H, et al.: Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005, 107:497–508.
Paleacu D, Barak Y, Mirecky I, Mazeh D: Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer’s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry 2008, 23:393–400.
Mintzer JE, Tune LE, Breder CD, et al.: Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007, 15:918–931.
Pollock BG, Mulsant BH, Rosen J, et al.: A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007, 15:942–952.
Wooltorton E: Risperidone (Risperdal): increased rates of cerebrovascular events in dementia trials. CMAJ 2002, 167:1269–1270.
Wooltorton E: Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004, 170:1395.
Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic treatment for dementia. Meta-analysis of randomized, placebo-controlled trials. JAMA 2005, 294:1934–1943.
Rochon PA, Normand SL, Gomes T, et al.: Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008, 168:1090–1096.
Schneider LS, Tariot PN, Dagerman KS, et al., for the CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006, 355:1525–1538.
Sultzer DL, Davis SM, Tariot PN, et al.: Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008, 165:844–854.
Rabins PV, Lyketsos CG: Antipsychotic drugs in dementia. What should be made of the risks? JAMA 2005, 29:1963–1965.
Wang PS, Schneeweiss S, Avorn J: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005, 353:2335–2341.
Schneeweiss S, Setoguchi S, Brookhart A, et al.: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007, 176:627–632.
Passmore MJ, Gardner DM, Polak Y, Rabheru K: Alternatives to atypical antipsychotics for the management of dementia-related agitation. Drugs Aging 2008, 25:381–398.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kirshner, H.S. Controversies in behavioral neurology: The use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia. Curr Neurol Neurosci Rep 8, 471–474 (2008). https://doi.org/10.1007/s11910-008-0075-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-008-0075-1